Brian Petuch, RBP, CBSP

Corporate Biosafety Officer, Merck & Co, Inc., West Point, Pennsylvania

09. Large-scale Biosafety

Large-scale Biosafety will review biosafety for work at large-scale, which the NIH rDNA Guidelines defines as >10L. The course will review Appendix K from GLSP to BSL-3 LS, with a focus on primary and secondary containment. It will review basic bioprocessing steps, such as fermentation/cell culture and purification technologies. Examples of classic and newer single use technologies will be provided. Pearls and pitfalls of the various technologies will be discussed, using various scenarios. The course will include a review of risk assessment techniques used for large scale bioprocesses and a discussion of large-scale related to vaccines, viral vectors, and recombinant proteins.

2024-02-28T17:15:35-06:00February 27th, 2024|

11. Large-scale Biosafety

Large-scale Biosafety will review biosafety for work at large-scale, which the NIH rDNA Guidelines defines as >10L. The course will review Appendix K from GLSP to BSL-3 LS, with a focus on primary and secondary containment. It will review basic bioprocessing steps, such as fermentation/cell culture and purification technologies. Examples of classic and newer single use technologies will be provided. Pearls and pitfalls of the various technologies will be discussed, using various scenarios. The course will include a review of risk assessment techniques used for large scale bioprocesses and a discussion of large-scale related to vaccines, viral vectors, and recombinant proteins.

2023-07-18T06:19:38-05:00March 17th, 2023|

Large-scale Biosafety

Large-scale Biosafety will review biosafety for work at large-scale, which the NIH rDNA Guidelines defines as >10L. The course will review Appendix K from GLSP to BSL-3 LS, with a focus on primary and secondary containment. It will review basic bioprocessing steps, such as fermentation/cell culture and purification technologies. Examples of classic and newer single use technologies will be provided. Pearls and pitfalls of the various technologies will be discussed, using various scenarios. The course will include a review of risk assessment techniques used for large scale bioprocesses and a discussion of large-scale related to vaccines, viral vectors, and recombinant proteins.

2024-01-15T17:46:27-06:00April 19th, 2022|
Go to Top